Diese Veranstaltung hat bereits stattgefunden
Kongress18th EURETINA Congress
European Society Congress of Retina Specialists 20181020 Wien, Österreich
Veranstaltungsnummer: 26991
Zertifizierung:
genehmigt
CME Max: 27
Kategorie:
Kategorie:
Gebühren ab:
150,00 EUR
verfügbare Plätze:
unbegrenzt
Sprache:
Englisch
Zum Kalender hinzufügen
-
Datum
20.09.2018, 09:00 - 23.09.2018, 13:30Veranstalter
EURETINAKurzbeschreibung
The 18th EURETINA Congress will be held in Vienna, Austria. The scientific program will comprise a variety of symposia, poster sessions, instructional and surgical courses, video and free paper presentations and several satellite meetings. The main topics of this conference are ocular oncology for surgical and medical retina specialists, novelties and late breaking developments in retina and technology, AMD and evidence based treatment in the AntiVEGF Era.Gebühren
Fachärzte
Teilnehmer max.
unbegrenzt
Gebühren ab
400,00 EUR
Earlybird bis 20.09.2018
350,00 EUR
Hinweis
EURETINA Member:
Before 20 Sept - 350 €
20-23 Sept - 400 €
Non-Member:
Before 20 Sept - 450 €
20-23 Sept - 500 €
Healthcare Professional:
Before 20 Sept - 175 €
20-23 Sept - 225 ۀrzte/-innen in Weiterbildung
Teilnehmer max.
unbegrenzt
Gebühren ab
240,00 EUR
Earlybird bis 20.09.2018
190,00 EUR
Hinweis
Trainee/ Resident Member:
Before 20 Sept - 190 €
20-23 Sept - 240 €
Trainee/Resident Non-Member:
Before 20 Sept - 210 €
20-23 Sept - 260 €medizinisches Fachpersonal
Teilnehmer max.
unbegrenzt
Gebühren ab
200,00 EUR
Earlybird bis 20.09.2018
150,00 EUR
Hinweis
k.A.Industriemitarbeiter/-innen
Teilnehmer max.
unbegrenzt
Gebühren ab
1.500,00 EUR
Earlybird bis 20.09.2018
1.300,00 EUR
Hinweis
k.A.Sponsoren
Alcon Deutschland GmbH
Alimera Sciences Ophthalmologie GmbH
Allergan GmbH
Bausch + Lomb
Bayer HealthCare AG
D.O.R.C. Deutschland GmbH
Ellex
Heidelberg Engineering GmbH
ifa systems AG
MEyeTech GmbH
NIDEK Inc.
Novartis Pharma GmbH
Optos GmbH Deutschland
Quantel Medical
Roche Pharma AG
Théa Pharma GmbH
Topcon
ZEISS
-
Thursday 20th September, 2018 EURETINA Main Session 1:
Ocular Oncology for surgical and medical retina specialists09:00 - 10:30 Introduction S. Seregard How modern imaging can aid in the differential diagnosis of small intraocular tumours H. Heimann Intravitreal treatment of radiation - and tumor - associated macular edema L. Zografos How to diagnose intraocular lymphoma - clinical presentation and biopsy techniques N. Bornfeld Surgical resection as an alternative to enucleation in large uveal melanoma - risks and benefits N. Bechrakis Prediction of metastatic disease in patients with uveal melanoma and screening recommendations B. Damato Critical bevaluation of systemic, intracameral and opthalmic artery chemotherapy for retinoblastoma M. Sagoo EURETINA Main Session 2:
The EURETINA guidelines for management of retinal disease11:00 - 12:30 Where is anti-VEGF therapy now: achievements and challenges Neovascular AMD: the ten key messages U. Schmidt-Erfurth Diabetic macular edema the ten key messages F. Bandello Vein occlusion: the ten key messages A. Loewenstein A state-of-the-art in endophthalmitis in anti-VEGF therapy A. Grzybowski The future needs and progress in anti-VEGF therapy D. Martin Discussion End of session EURETINA Main Session 3:
Decision making in challenging cases14:30 - 16:00 Should we treat subclinical CNV discovered by OCTA? S. Schmitz-Valckenberg Is it valuable to tolerate subretinal fluid in the treatment of type 1 CNV? A. Tufail If a PDR associated with DME is treated by anti-VEGF, is it safe to space out injections? R. Silva Do you stop anti-VEGFs in persistent RVO related CME without binocular problems? JR. Vingerling Should we operate early myopic foveoschisis to avoid complications? Y. Ikuno Can we expect visual improvement in some lamellar macular hole after surgery? R. Schumann What to do in chronic CSCR when serous retinal detachment reccurs after PDT? C. Boon How to manage Coat's disease with central macular lipid exudation? A. Daruich-Matet Discussion End of session Friday 21st September, 2018 EURETINA Main Session 4:
Novelties and late breaking developments in
Retina & Technology8:00 - 9:30 Recent advances in surgical techniques: new trends and expectations AI-based analysis: A revolution in imaging Genetic therapy: reinventing genes Novel understanding of normal and abnormal retinal vascularization under the light of new imagery Late Breaking Presentations Discussion End of session EURETINA Main Session 5: AMD 12:00 - 13:30 Dry AMD - how to proceed? Current management of exudative AMD F. Holz New studies in exudative AMD P. Dugel When can we define a patient as a non-responder A. Loewenstein Long-term effects of anti-VEGF M. Goldstein Biomarkers on CNV M. Battaglia Parodi Guts, genes and AMD M. Zinkernagel Saturday 22nd September, 2018 EURETINA Main Session 6:PDR in 2018:
Evidence based treatment in the AntiVEGF Era8:00 - 9:30 Pathophysiology of macular edema, diabetic and other M. Larsen Retinal photocoagulation : Pro and Cons E. Pilotto Anti VEGF and proliferative diabetic retinopathy trial data: S. Sivaprasad / J. Wells How might Protocol S and Clarity results be generalized in current practice R. Schlingemann Cost effectiveness of antiVEGF therapy for PDR N. Bressler Vitrectomy in PDR 2018 D. Steel Chaired panel discussion on pragmatic evidence based management of PDR
in 2018 (specific scenarios):
i. Severe NPDR, treat don’t treat? ii. Low risk NVD/E treat don’t treat: what with? iii. HRC: no macular edema iv. HRC: with macular edema v. Persistent NV after standard PRP vi. Mild vitreous haemorrhage after full PRP vii. Florid PDR with no previous treatment End of session EURETINA Main Session 7: Imaging 16:30 Agreement between OCT angiography and FA/ICG in neovascular AMD U. Chakravarthy Single layer OCT, OCT angiography and fuctional correlates in diabetic patients E. Midena Retinal vascular biomakers forAlzheimer's disease T. Peto Adaptive optics-SLO single photoreceptor imaging and Psychophysics W. Harmening The use of artificial intelligence / deep learning in the analysis of retinal images P. Keane Full volume render virtual reality OCT P. Maloca Discussion End of session EURETINA Main Session 8: Research Session 11:00 - 12:30 Genetics in retinal disease B. LeRoy Genetics in retinal disease C.C.W. Klaver Gene therapy achromatopsia CNGA3 D. Fischer Gene therapy achromatopsia CNGB3 J. Bainbridge Optogenetics for end-stage retinis pigmentosa (2 perspectives)
Cell therapy for age-related macular degenerationS. Kleinlogel Gene therapy for retinis pigmentosa R. MacLaren The Argus II retinal implant for retinis pigmentosa S. Rizzo The AMS epiretinal implant for retinis pigmentosa F. Gekeler Discussion End of session Sunday 23 September, 2018 EURETINA Main Session 9: Vitreoretinal surgery 10:00 - 11:30 Retinal detachment outcomes in IRIS (Intelligent research in sight)
Intraocular foreign body removal: Tips and tricksPaediatric retinal detachment S. Chien Wong Surgical management of optic pit maculopathy: Which is the best technique? J. Garcia Arumi Endoillumination buckle Cold-fusion Retinopathy of prematurity EURETINA Main Session 10: Myopia - a full update 12:00 - 13:30 Genetics, risk factors and epidemiology of myopia C.C.W. Klawer Progression of myopia and myopic maculopathy J. Jonas Prevention of myopia and of ist evolution G. Cheung Refractive and lens surgery in highly myopic eyes and lens from the retina perspective A. Grzybowski Modern imaging of the retina in high myopia Y. lida Domeshape macula news Myopic choroidal neovascularization management update G. Querques Update on modern surgery in highly myopic eyes to achieve best possible results R. Tadayoni New technics for closing myopic macular holes M. Figueroa
Meet the Experts, OD-OS Navilas® Booth C207Friday, September 21st 2018
10:00 am - D. Maltsev - Macroaneurysms
Saturday, September 22nd 2018
10:00 am - J. Chhablani - MSP vs. PDT for CSCR
13:30 pm - I. Kozak - Coat's Disease
Sunday, September 23rd 2018
10:00 am - F. Amorosa - The future of PRP Treatment
-
Reed Messe Wien
EURETINA
Temple House
Temple Road, Blackrock
Tel.: +353 (0)1 210 0092
Fax: +353 (0)1 209 1112 -
Please contact the organizer for further information.